Eli Lilly reports 79% response and 100% disease‑control in Phase 1 ovarian‑cancer ADC trial
Eli Lilly presented Phase 1 results for its folate‑receptor‑alpha‑targeting antibody‑drug conjugate sofetabart mipitecan (Sofe‑M) combined with bevacizumab in platinum‑sensitive ovarian cancer. The 33‑patient cohort achieved a confirmed objective response rate of 79% (79.3% among measurable disease) and a disease‑control rate of 100%, with activity across FRα expression levels and prior PARP‑inhibitor exposure. The regimen was dosed at 4 mg/kg Sofe‑M plus 15 mg/kg bevacizumab, and safety was consistent with known profiles, with the most common any‑grade adverse events being epistaxis (73%) and nausea (73%).
Why it matters
The company says the data support continued advancement of Sofe‑M in its three‑part FRAmework‑01 Phase 3 program, potentially expanding Lilly’s oncology pipeline and future revenue streams. Seeking Alpha notes the announcement helped lift LLY shares, indicating market enthusiasm for the early‑stage results.
Key facts
- 1The Phase 1 study enrolled 33 women with platinum‑sensitive ovarian cancer. prnewswire.com
- 2Confirmed objective response rate (cORR) was 79% overall and 79.3% (23/29) among patients with measurable disease. prnewswire.com
- 3Disease‑control rate (DCR) was 100%. prnewswire.com
- 4Patients received Sofe‑M at 4 mg/kg plus bevacizumab at 15 mg/kg. prnewswire.com
- 5Median number of prior systemic regimens was three (range 1–6). prnewswire.com
- 6Median follow‑up was 6.2 months for duration of response and 10.2 months for progression‑free survival (both not reached). prnewswire.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.